GLP-1 year two cost effectiveness study abstract

Forbes: Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...